gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · FDMTHealthcareBiotechnology

4D Molecular Therapeutics, Inc. Common Stock (FDMT)

$12.28+2.76%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$11.95▲ 6.51% in range
Nov 3, 2025Low $7.19 · High $16.76Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

4D Molecular Therapeutics closed at $12.28 on Nov 4, up 2.76%, 26.7% below its 52-week closing high. Volume of 765.3K shares was 0.81× its 20-day average (close to normal).

Split-adjusted performance: -2.2% over one month, +17.9% over six months, +9.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $3.78M, up 25106.7% from a year earlier, with a net margin of -1929.0%.

Short interest was 11.5M shares at the Oct 15 settlement, up 2.6% from the prior report (21.6% of float, 12.0 days to cover).

Market cap$678.4M55.2M shares
Revenue · quarter$3.8M+25106.7% YoY
Diluted EPS$-1.04—
P/E · TTM—P/S 7.4×
Net margin-1,929.0%Gross 100.0%
Dividend yieldNone
52-week range7.19 – 16.76−26.7% from high
Volume765.3K0.81× 20-day avg
Volatility · 60d76.2%Annualised
Short % of float21.6%12.0 days to cover
Net cash$341.7MCash $361.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −5.0%1M −2.2%3M +16.4%6M +17.9%YTD +63.7%1Y +9.4%3Y +15.5%5Y −60.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum78
Revenue growth100
Net margin22
Value (low P/E)—
Size65

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short11.5M+2.6% vs prior
Days to cover12.0Settled Oct 15
% of float21.6%
Short vol. 10d53.7%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
FDMT4D Molecular Therapeutics$12.28+2.76%+17.9%+25106.7%−1929.0%—$678.4M
AURAAura Biosciences$6.65+6.57%−19.8%———$689.6MCompare
CADLCandel Therapeutics$9.05+2.61%+18.6%———$692.5MCompare
SLDBSolid Biosciences$6.52+3.82%−9.4%———$699.1MCompare
ATTOAttovia Therapeutics$15.60+2.16%————$712.2MCompare
SANASana Biotechnology$2.56+4.92%−29.7%———$766.4MCompare
DNAGinkgo Bioworks Holdings$11.65+8.27%+15.6%−48.5%−231.7%—$784.5MCompare
CGEMCullinan Therapeutics$12.49−20.70%−16.7%———$803.8MCompare
ENTXEntera Bio$3.11+1.97%+148.8%———$540.9MCompare

News about 4D Molecular Therapeutics

All news →
4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research · 2d ago▲ Positive4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD PopulationGlobeNewswire Inc. · Jul 18, 2026▲ Positive

Quick answers

What does 4D Molecular Therapeutics do?
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies.
What is FDMT's market cap?
$678.40M, based on the Nov 4 close of $12.28.
Does 4D Molecular Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of FDMT is sold short?
11.5M shares, 21.6% of float, as of Oct 15, 2026.
What sector is FDMT in?
Healthcare, in the Biotechnology industry.

About 4D Molecular Therapeutics

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

HQ: Emeryville, CA196 employeesListed Dec 11, 20204dmoleculartherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology